Medicine-Food Homology Bioactives for Polyendocrine Metabolic Ovarian Syndrome: Multi-Target Mechanisms and Functional Food Translation.

Authors
Category Systematic review
JournalMolecules (Basel, Switzerland)
Year 2026
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is characterized by insulin resistance, hyperandrogenism, chronic inflammation, and oxidative stress, with a global prevalence of 10-13% and limited current drug treatments. Medicine-Food Homology (MFH) materials are rich in bioactive compounds such as polyphenols, flavonoids, and polysaccharides, offering potential multi-target nutritional interventions for PMOS, although safety data remain limited mainly to single compounds. A systematic search of the literature was conducted across PubMed/MEDLINE, Web of Science CNKI, and Wanfang Data, spanning from database inception to August 2026, utilizing predefined search terms and inclusion/exclusion criteria. This review summarizes research on MFH-derived bioactive compounds in PMOS, covering active component identification, network pharmacology-based target prediction, key signaling pathways (PI3K/AKT, AMPK, NF-κB, Nrf2/HO-1), and formulation strategies including green extraction, nano-encapsulation, and controlled release. It further discusses functional food development from five perspectives: meal replacement powders, functional teas, fermented beverages, dietary supplements, and compound formulations. Key bottlenecks hindering commercialization are analyzed, including insufficient high-quality clinical evidence, unclear dose-response relationships, and limited long-term stability data. Future directions are proposed, such as organoids, organ-on-a-chip, AI-driven formulation optimization, and international multicenter trials. In summary, MFH bioactive compounds show potential as multi-target interventions for PMOS; however, most mechanistic evidence comes from non-PMOS metabolic models, and direct PMOS-specific evidence is limited. Their translation from empirical use to evidence-based intervention requires PMOS-specific preclinical validation, randomized controlled trials, safety assessments, bioavailability evaluation, and standardized product validation, alongside collaborative efforts across research paradigms, technology development, and industrial translation.
Epistemonikos ID: a20d0f690c819b7dcbc56100e9e0b0c061e42939
First added on: Oct 28, 2026